~5% of cases are hereditary. In MEN2, knowing RET can justify prophylactic thyroidectomy — saving lives.
helixXY analyzes FOXE1, NKX2-1 (papillary), RET (MEN2/medullary), DIRC3, DICER1 and PTEN (Cowden) — the main thyroid cancer susceptibility loci.
The thyroid is one of the most finely regulated glands in the body — and one of the most heritable when it comes to cancer. ~5% of cases have hereditary origin, with well-defined syndromes: MEN2 (RET), Cowden (PTEN), DICER1, and familial forms of papillary thyroid cancer.
The most dramatic case is Medullary Thyroid Carcinoma in MEN2: pathogenic RET variants have penetrance near 100%. Early identification enables prophylactic thyroidectomy in childhood, before tumor development — one of the few situations in medicine where genetic testing radically changes surgical management.
For papillary cancer (~80% of cases), GWAS identified risk loci (FOXE1, NKX2-1, DIRC3) that help stratify who benefits from ultrasound surveillance in families with history.
Pathogenic RET variants justify prophylactic thyroidectomy in childhood in MEN2 carriers — before MTC develops. It saves lives.
Papillary cancer detected early has >95% 10-year survival. Genetics anticipates risk and enables targeted surveillance.
Use your file from 23andMe, Genera, AncestryDNA, etc. Within 15 minutes of upload, your report is ready.
Thyroid cancer is 3× more common in women — one of the largest sex disparities in oncology. Knowing the genetics is especially relevant.
Photo from Pexels
Thyroid ultrasound is quick, painless, and detects subcentimeter nodules. In FOXE1/RET/PTEN risk carriers, annual surveillance is recommended.
Photo from Pexels
FOXE1 and NKX2-1 (papillary), RET (MEN2/medullary), DIRC3, DICER1 (syndrome), and PTEN (Cowden) — covering hereditary syndromes and polygenic susceptibility.
Forkhead Box E1 — transcription factor essential for thyroid gland development. The strongest locus associated with papillary thyroid cancer in every international GWAS. The rs965513 (A-allele) variant raises risk by more than 70% per allele — uncommonly large effect for a complex disease.
NK2 Homeobox 1 (also known as TTF-1) — second main risk locus for papillary thyroid cancer. Master regulator of thyroid and pulmonary development. NKX2-1 variants alter thyrocyte differentiation and contribute to tumorigenesis.
REarranged during Transfection — receptor tyrosine kinase. Pathogenic germline variants cause Multiple Endocrine Neoplasia type 2 (MEN2A/MEN2B) and familial Medullary Thyroid Carcinoma (MTC). Penetrance near 100% — carriers require prophylactic thyroidectomy in childhood.
Disrupted In Renal Carcinoma 3 — long non-coding RNA with emerging role in thyrocyte regulation. DIRC3 polymorphisms modulate IGF2BP2 expression and affect papillary thyroid cancer susceptibility, particularly in European-ancestry populations.
Ribonuclease essential for microRNA biogenesis. Germline variants in DICER1 cause DICER1 syndrome — predisposition to multiple tumors including pleuropulmonary blastoma, multinodular thyroid goiter, papillary and follicular thyroid cancer, especially at young age.
Phosphatase and Tensin Homolog — tumor suppressor gene. Germline variants cause Cowden Syndrome / PTEN Hamartoma — predisposition to follicular thyroid cancer (~30% lifetime risk), breast cancer, endometrial cancer, and benign tumors. Important to screen when multiple thyroid nodules are present.
Additional loci also analyzed: The report also includes variants in IGF2BP2, ATM, CHEK2, SDHA/B/C/D, RAD51C and other smaller-effect loci identified in differentiated thyroid cancer GWAS meta-analyses.
Photo from Pexels
Thyroid cancer has one of the best cure rates among cancers — 5-year survival above 98% for papillary subtype diagnosed early. Knowing the genetic risk enables targeted surveillance and informed peace of mind.
For RET/MEN2 carriers, genetic knowledge is literally life-saving: prophylactic thyroidectomy in childhood prevents MTC, which would otherwise be diagnosed too late.
Papillary (FOXE1, NKX2-1), follicular (PTEN, DICER1), and medullary (RET) cancer genes are analyzed differentially.
Pathogenic RET variants are identified with high reliability — diagnosis that may justify prophylactic thyroidectomy.
For papillary cancer (non-MEN2), polygenic score based on FOXE1, NKX2-1, DIRC3 and dozens of additional loci.
PTEN (Cowden), DICER1, and RET (MEN2) — syndromes affecting multiple organs. Integrated surveillance considers all risks.
As ATA and ClinVar classifications evolve, your report follows — at no additional cost.
Your data is processed with AES-256 encryption in zero-knowledge architecture. Full GDPR compliance.
Most thyroid cancers are asymptomatic early on — discovered incidentally on imaging or physical exam.
Painless lump in the anterior neck region, noticed by you or by physician on physical exam. Most are benign, but require investigation by USG.
Voice change lasting more than 3–4 weeks, especially without prior cold, may indicate recurrent laryngeal nerve compression by tumor.
Sensation of "lump" or progressive dysphagia — tumor may compress esophagus. Investigate when associated with weight loss.
Palpable lymph nodes in the neck, particularly lateral chains — may indicate metastasis from primary thyroid tumor.
Large tumor may compress trachea. Persistent cough without identified pulmonary cause justifies cervical evaluation.
Nodule that grows rapidly (weeks) requires urgent evaluation — may indicate anaplastic carcinoma (rare but aggressive) or other poorly differentiated forms.
Our analysis integrates international GWAS data with over 25,000 cases, ClinVar classifications, and American Thyroid Association (ATA), NCCN, and ESMO guidelines.
Important medical notice: The information provided by helixXY is for educational purposes only. RET variants suspected of MEN2 must be confirmed by diagnostic sequencing and genetic counseling before any surgical decision. Diagnosis of thyroid cancer requires evaluation by endocrinologist, thyroid ultrasound, and fine-needle aspiration when indicated.
Upload your genetic file and receive your thyroid cancer risk report in under 15 minutes.
No spam. Cancel anytime.